Organon & Co. (NYSE: OGN) Reduces Board Size Following Resignation of Director

Organon & Co., a Delaware-based pharmaceutical company trading on the NYSE under the symbol OGN, recently disclosed a change in its board structure in an 8-K filing with the Securities and Exchange Commission.

According to the filing dated December 20, 2024, Martha E. McGarry, a member of the company’s Board of Directors, tendered her resignation. In response to her resignation, the Board took immediate action to reduce its size to eleven members, effectively filling the vacancy created by McGarry’s departure.

The SEC filing did not provide specifics regarding the reasons for McGarry’s resignation or details on any replacement for her position on the Board. Organon & Co.’s Board now consists of eleven members post the adjustment.

The filing indicated that Exhibit 104 contains the cover page of the Current Report on Form 8-K formatted in Inline XBRL, providing transparency and accessibility to interested parties.

Organon & Co. affirmed the change by authenticating the report through its General Counsel & Corporate Secretary, Kirke Weaver. The signing took place on December 23, 2024.

No further details were disclosed in the filing regarding future plans or implications of the board restructuring.

Investors and stakeholders of Organon & Co. may look forward to updates from the company regarding any additional developments following these changes in its leadership structure.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Organon & Co.’s 8K filing here.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.